title: [Treatment with beta-erythropoietin in lung cancer--effectiveness and quality of life improvement in clinical practice].
abstract: Anemia is common among patients with malignant tumors, due to the disease and chemotherapy. Anemia decreases patient's quality of life, and worsens the dose-intensity of chemotherapy. The aim of this retrospective data-analysis was to evaluate quality of life and hemoglobin levels in 19 consecutive lung cancer patients receiving beta-erythropoietin, due to chemotherapy induced anemia. A self developed, patient source data based quality of life questionnaire was used. The mean pre-erythropoietin hemoglobin concentration of the patients was 96.31±6.72 g/L (mean±SD), the post-treatment hemoglobin concentration 111.63±14.05 g/L (p<0.05). During the chemotherapy of the 19 patients with lung cancer, transfusion was given only four times. The mean quality of life total score of the patients increased significantly during erythropoietin treatment that was resulted by the improvements of scores determining dizziness, tachycardia, and fatigue. Main limitations of this real life data analysis are low patient number and the lack of validation in the used questionnaire. In summary, according to our experiences, the use of beta-erythropoietin in patients with lung cancer results improved quality of life and a low rate of transfusions.
authors.affiliation: Semmelweis Egyetem, Altalános Orvostudományi Kar, Pulmonológiai Klinika, Budapest. tamasi@pulm.sote.hu
authors.forename: Lilla
authors.initials: L
authors.lastname: Tamási
authors.forename: Gabriella
authors.initials: G
authors.lastname: Gálffy
mesh_terms: D000328:Adult; D000368:Aged; D000747:Anemia, Hypochromic / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001803:Blood Transfusion / Q000706:statistics & numerical data; D004244:Dizziness / Q000209:etiology / Q000517:prevention & control; D004921:Erythropoietin / Q000008:administration & dosage*; D005221:Fatigue / Q000209:etiology / Q000517:prevention & control; D005260:Female; D006397:Hematinics / Q000008:administration & dosage; D006454:Hemoglobins / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D011994:Recombinant Proteins; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D013610:Tachycardia / Q000209:etiology / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin